A Closer Look at Spravato (Esketamine)
Topic: What do we know about the prescribed dosing?
As the P.R. machine kicks into gear to support the launch of Spravato/Esketamine, the first FDA approved Ketamine-derived treatment, Kevin Nicholson (President, CEO of Ketamine Wellness Centers) digs into the details that tend to receive less attention.
One thing that raised the eyebrows of everybody on the clinical team here at KWC relates to the recommended dosing of Spravato. On this episode, we discuss:
- What is the recommended dosing during the stabilization and maintenance treatment phases?
- Is the dosing variable from patient to patient or fixed?
- What are the implications of utilizing a non-variable prescription for dosing?
Our experienced team of physicians, nurse practitioners, and research staff break down each topic in short, to-the-point podcasts, which you may listen to on your own time by subscribing to Ketamine Wellness Centers on iTunes or tune in by following the KWC blog.